During these Dynamic Talks, 4 top experts will bring Visionary Talk sessions (3×20’) bringing answers to relevant discussions that are going on ;

• How can international collaboration between HTA and regulatory bodies promote knowledge exchange, efficiency of information production thus driving transparency of process of assessment and decision-making?
   
• Exploring a novel approach to RWE generation. How can the pharmaceutical and biotech industry leverage new technologies to get evidence faster and more patient-focused than the standard?
   
• Optimising  External Reference Pricing (ERP) in a challenging global scenario. How can a company strategically approach the challenges of ERP?

During these Dynamic Talks, 4 top experts will bring Visionary Talk sessions (3×20’) bringing answers to relevant discussions that are going on ;

• Why a strategic approach is key to digital transformation: from the adoption and implementation of advanced technologies to organisational changes, collaboration, and supportive leadership
   
• How is big data and AI technology driving market access strategy and practice? How can AI and machine learning help maximise clinical trial data, identify RWE gaps and generation of evidence to meet HTA requirements?
   
• Assessing how predictive analytics can be deployed to inform pricing strategies, determine appropriate launch sequences, and optimise discounts

During these Dynamic Talks, 4 top experts will bring Visionary Talk sessions (3×20’) bringing answers to relevant discussions that are going on ;

• Exploring real-life examples of successful tendering in medical devices and pharmaceuticals
   
• EValue-based tendering in Life Sciences: assessing challenges and opportunities for adding quality criteria beyond price-only evaluation of tenders
   
• Leveraging latest technologies to evaluate tender opportunities and find the optimal price for the product

During these Dynamic Talks, 4 top experts will bring Visionary Talk sessions (3×20’) bringing answers to relevant discussions that are going on ;

• Value-based pricing and contracting for innovative MedTech: assessing main barriers and opportunities
   
• How are payers embracing digital health tools such as connected devices and telemedicine? Exploring reimbursement models for digital health products with country-focused examples
   
• Learning how to successfully achieve payer reimbursement with outcomes-based risk-sharing models.
   
• From Device-Focused to Service-Focused: capturing the value-based procurement opportunity to get ahead in a competitive marketplace

During these Dynamic Talks, 3 top experts will bring crystal ball sessions (3×20’) bringing answers to relevant discussions that are going on ;

• Assessing top barriers for value-based pricing adoption in pharma. What are the challenges facing value-based pricing implementation? How can we achieve a worthy transition to outcomes-based contracts? 
• Exploring alternative pricing and contracting models for next generation therapies. What are the main tendencies for contracting preferences based on the product value? How can the industry successfully manage the challenges in ATMPs pricing settings and reimbursements?    
• Indication-based pricing of innovative medicines – pragmatic or idealistic?    

During these Dynamic Talks, 4 top experts will bring visionary talks (4×15’) bringing answers to relevant discussions that are going on ;

• Discovering how predictive analytics can be deployed to inform pricing strategies, determine appropriate launch sequences and optimise discounts
• Harnessing the value of Big Data: how can the industry create real and identifiable gains to make a meaningful impact? Is building an advanced analytics capability worth the investment?
• Exploring disruptive technologies for improved transparency, market access and collaboration between payers, HTAs, manufacturers and patients    

During these Dynamic Talks, 3 top experts will bring crystal ball sessions (3×20’) bringing answers to relevant discussions that are going on ;

• What impact will COVID-19 have on the future of pricing and market access? Achieving pricing excellence in uncertain times
• Analysing the successful revival of public-private partnerships. Will these collaborations impact positively the life sciences industry and the access and optimal prices of innovative and costly drugs?    
• How can the Healthcare sector leverage the accelerated switch to digital experienced in 2020 in a way that could bring operational and financial benefits long after the pandemic?    

During these Dynamic Talks, 2 top experts will bring rapid fire sessions (2×12’) bringing answers to relevant discussions that are going on ;

• Understanding the implications of the pandemic on life sciences pricing strategies
• How will pricing be managed within an overall platform to develop treatments for COVID-19 while achieving affordable access?
• Will payers deal differently with assessing and valuing products ?    

During these Dynamic Talks, 2 top experts will bring visionary talks (2×20’) bringing answers to relevant discussions that are going on ;

• How can we harmonise processes in HTA submissions?
• How can we harmonise processes across the EU?
• How are different HTA agencies operating?    

During these Dynamic Talks, 3 top experts will bring visionary talks (3×20’) bringing answers to relevant discussions that are going on ;

• Creating a harmonised ATMP process and a continued pathway for the EU to benefit from innovative and life changing ATMPs
• Streamlining regulatory requirements for clinical trials with ATMPs across Europe by ensuring smooth implementation of the upcoming clinical trial regulation
• Is there a shift toward more innovative medicines such as cell and gene therapies that may change future treatment paradigms and future pricing and reimbursement policies?    

During these Dynamic Talks, 3 top experts will bring rapid fire sessions (3×12’) bringing answers to relevant discussions that are going on ;

• Developing strategies focused on demonstrating real value and minimising risk
• Understanding the future of launch excellence and how to prepare
• Demonstrating real, measurable value to re-engineer the approaches to commercialisation and pricing    

10th EPP Life Sciences Pricing Forum 2021 in Munich

Presentation by: Cube RM, Bavarian Nordic and CMR Surgical

EPP Dynamic Talk in partnership with Cube RM "The Ideal Tender Excellence Journey for the Life Sciences"

• 7 steps for success in Tendering Framework with George Boretos, Co- Founder & Co-CEO - Cube RM                - Managing end - to - end the tender cycle, from Tender Discovery to Awardation.                - Enabling technologies for Tendering Excellence.
•  Tender Industry Benchmarking & Key Challenges with Nico Bacharidis, Business Advisor - Cube RM, Founder & CEO – Growpal                - Key success factors for tendering in Life Sciences                - Current status of the market (industry benchmarks)
• ️ Using Innovative Technologies to excel in Tendering with Laura Wardoyo, Director – Global Head of Tenders & Pricing – Bavarian Nordic                - Key company challenges                - The implemented solution and key benefits
 
• Panel with the President of the EPP (Pol Vanaerde) moderating the discussion